- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03592667
Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
Effect of Dapagliflozin on the Blood Pressure Variability and the Ambulatory Arterial Stiffness Index in Individuals With Stage I Hypertension Without Diabetes Mellitus
The prevalence of arterial hypertension has remained the same in the last 5 years, however, almost 50% of the population continues without an adequate adjustment according to the National Health Survey of the Midway 2016.
It has been shown that the variability of blood pressure (VBP) during 24 h and visit-visit is associated with cardiovascular diseases (CVD) over the effect of blood pressure (BP) itself. On the other hand, arterial stiffness is well known as an independent factor of CVD risk and for its evaluation the ambulatory arterial stiffness index (AASI) has been proposed. AASI and the VPA obtained through an evaluation by ambulatory BP monitoring (ABPM) individual of 24 h.
Dapagliflozin is an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) for the treatment of diabetes mellitus type 2 (DM2) that promotes natriuresis and osmotic diuresis, which produces a decrease in plasma volume and a decrease in BP.
The aim of ths study is to evaluate the effect of dapagliflozin on VBP and AASI in individuals with stage I hypertension whitout DM2.
The investigators hypothesis is that the administration of dapagliflozin decreases the VBP and AASI in individuals with stage I hypertension whitout DM2.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A randomized, double-blind, placebo-controlled clinical trial in 20 patients with a diagnosis of stage I hypertension without DM2.
They will be assigned randomly two groups of 10 patients each to receive 10 mg of Dapagliflozin (Forxiga, Astra Zeneca) or placebo, one per day before breakfast during 12 weeks.
There will be calculated indices of VBP: 24 h, daytime and night-time standard deviation (SD), coefficient of variation (CV), 24 h weighted SD, Day-to-nigth BP changes and average real variability (AVR). On the other hand, AASI will be calculated with a linear regression.
This protocol it's already approved by the local ethics committee and written informed consent it's going to be obtained from all volunteers.
Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentages for variable qualitative. Qualitative variables will be analyzed by X2 o exact fisher test, will be used for differences inter-group. Mann-Whitney U Test and Wilcoxon Test for the within-groups differences. It will be considered statistical significance p ≤0.05.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Manuel Gonzalez, PhD
- Phone Number: 34212 +52-10-58-52-00
- Email: uiec@prodigy.net.mx
Study Contact Backup
- Name: LIZET YADIRA ROSALES, PhD
- Phone Number: 34212 +52-10-58-52-00
- Email: lizet.rosales@gmail.com
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Recruiting
- Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara
-
Contact:
- Manuel Gonzalez, PhD
- Phone Number: 34212 +52-10-58-52-00
- Email: uiec@prodigy.net.mx
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent signed
- Patients both sexes, age between 30 and 60 years
- Diagnosis of stage I hypertension according ACC/AHA (American college of cardiology/American heart association) blood pressure between 130-139/ 80-89 mmHg.
- Fasting plasma glucose < 100 mg/dl
- BMI >35 kg/m2
- Glomerular filtration rate > 60ml/min/1.73m2
Exclusion Criteria:
- Women with confirmed or suspected pregnancy
- Women under lactation and/or puerperium
- Hypersensibility to ingredients of intervention
- Physical impossibility for taking pills
- Known uncontrolled renal, hepatic, heart, thyroid or cardiovascular diseased
- Previous treatment for hypertension or depression
- Triglycerides ≥ 400 mg/dl
- Total cholesterol ≥ 240 mg/dl
- Worker per shift night
- Arrhythmia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin
Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
|
10 mg, one per day before breakfast during 12 weeks.
Other Names:
|
Placebo Comparator: Placebo
Placebo capsules, one per day before breakfast during 12 weeks.
|
One per day before breakfast during 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Indices of blood pressure: 24 h, daytime and night-time SD and CV, 24 h weighted SD, day-to-nigth BP changes and ARV
Time Frame: Baseline to Week 12
|
Blood pressure variability will be evaluated with ambulatory blood pressure monitoring
|
Baseline to Week 12
|
Ambulatory arterial stiffness index
Time Frame: Baseline to Week 12
|
Arterial stiffness will be evaluated with ambulatory blood pressure monitoring
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulse Pressure of 24 h
Time Frame: Baseline to Week 12
|
Will be evaluated with ambulatory blood pressure monitoring, systolic BP minus diastolic BP.
|
Baseline to Week 12
|
Mean arterial pressure of 24 h, daytime and nigth-time
Time Frame: Baseline to Week 12
|
Will be evaluated with ambulatory blood pressure monitoring, systolic BP minus diastolic BP/3, plus diastolic BP.
|
Baseline to Week 12
|
Heart rate of 24 h, daytime and nigth-time
Time Frame: Baseline to Week 12
|
Will be evaluated with ambulatory blood pressure monitoring.
|
Baseline to Week 12
|
Hypertensive load daytime and nigth-time
Time Frame: Baseline to Week 12
|
Will be evaluated with ambulatory blood pressure monitoring.
|
Baseline to Week 12
|
White coat hypertension
Time Frame: Baseline to Week 12
|
will be evaluated with ambulatory blood pressure monitoring
|
Baseline to Week 12
|
Fasting glucose levels
Time Frame: Baseline to Week 12
|
The fasting glucose levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12.
|
Baseline to Week 12
|
Total cholesterol
Time Frame: Baseline to Week 12
|
Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12
|
Baseline to Week 12
|
Triglycerides levels
Time Frame: Baseline to Week 12
|
Triglycerides levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12
|
Baseline to Week 12
|
High density lipoprotein (c-HDL) levels
Time Frame: Baseline to Week 12
|
c-HDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12
|
Baseline to Week 12
|
Creatinine levels
Time Frame: Baseline to Week 12
|
Creatinine levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques
|
Baseline to Week 12
|
Uric acid levels
Time Frame: Baseline to Week 12
|
Uric acid levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques
|
Baseline to Week 12
|
Body Weight
Time Frame: Baseline, week 4, week 8 and week 12
|
The body weight will be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12
|
Baseline, week 4, week 8 and week 12
|
Body Mass Index
Time Frame: Baseline, week 4, week 8 and week 12
|
Body Mas Index will be calculated at baseline, week 4, week 8 and week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12
|
Baseline, week 4, week 8 and week 12
|
Waist circumference
Time Frame: Baseline, week 4, week 8 and week 12
|
Waist circumference will be evaluated with the method proposed by ISAK.
|
Baseline, week 4, week 8 and week 12
|
Glomerular filtration rate
Time Frame: Baseline to Week 12
|
Glomerular filtration rate will be calculated at baseline and week 12 with the Cockcroft-Gault formula and the entered values reflect the Glomerular filtration rate at week 12
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: MANUEL GONZALEZ, PhD, University of Guadalajara
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAPA on VBP-AASI Hypertension
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Dapagliflozin
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaRecruitingLiver CirrhosisSpain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil